Inactive Instrument

Tricida, Inc.

Equities

TCDA

US89610F1012

Biotechnology & Medical Research

Tricida : to Present at the 37th Annual J. P. Morgan Healthcare Conference

January 03, 2019 at 12:31 am IST

Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 37^th Annual J. P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 11:30 am PT / 2:30 pm ET. Gerrit Klaerner, Ph.D., Tricida’s chief executive officer and president, will provide a company overview, business update and progress on the company’s key initiatives.

A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Tricida has successfully completed a pivotal Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. For more information about Tricida, please visit the company’s website at www.Tricida.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005417/en/

Latest news about Tricida, Inc.

Tricida, Inc. Went Out of Business	12/23/12	CI
First Motion for Exclusivity Period Extension Approved For Tricida, Inc.	01/23/01	CI
Fifth Amended Liquidation Plan Approved for Tricida, Inc.	23/23/23	CI
Fifth Amended Liquidation Plan Filed by Tricida, Inc.	22/23/22	CI
Fourth Amended Liquidation Plan Filed by Tricida, Inc.	12/23/12	CI
First Motion for Exclusivity Period Extension Filed by Tricida, Inc.	08/23/08	CI
North American Morning Briefing : China Data Helps -3-	18/23/18	DJ
North American Morning Briefing : Stock Futures -3-	11/23/11	DJ
Fourth Amended Disclosure Statement Approved for Tricida, Inc.	27/23/27	CI
Fourth Amended Disclosure Statement Filed by Tricida, Inc.	24/23/24	CI
Third Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	21/23/21	CI
Second Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	26/23/26	CI
First Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	24/23/24	CI
Motion for Asset Sale Approved for Tricida, Inc.	22/23/22	CI
Motion for Asset Sale Approved for Tricida, Inc.	22/23/22	CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc.	16/23/16	CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc.	16/23/16	CI
Tricida, Inc. Announces Resignation of David Bonita as Director	28/23/28	CI
Bidding Procedure Approved for Tricida, Inc.	26/23/26	CI
Tricida, Inc.(OTCPK:TCDA.Q) dropped from NASDAQ Composite Index	23/23/23	CI
Top Premarket Gainers	18/23/18	MT
Tricida, Inc.(NasdaqGS:TCDA) dropped from S&P TMI Index	18/23/18	CI
Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	18/23/18	CI
Tricida, Inc. Filed for Bankruptcy	11/23/11	CI
Motion for Asset Sale Filed by Tricida, Inc.	11/23/11	CI

Chart Tricida, Inc.

Duration

Period

More charts

Company Profile

Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+16.59%	4.44TCr
LONZA GROUP AG	+41.02%	3.98TCr
IQVIA HOLDINGS INC.	-10.62%	3.77TCr
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	3.15TCr
CELLTRION, INC.	-9.23%	2.7TCr
ICON PUBLIC LIMITED COMPANY	+12.34%	2.63TCr
UNITED THERAPEUTICS CORPORATION	+41.53%	1.38TCr
MEDPACE HOLDINGS, INC.	+31.49%	1.25TCr
BIO-TECHNE CORPORATION	-7.40%	1.13TCr

Other Biotechnology & Medical Research